Immorta Bio Combines Senolytic and Regenerative Therapies to Extend Lifespan by 70% in Animal Models

  • Immorta Bio published a peer-reviewed study showing a 70% lifespan extension in aging animal models using its SenoVax™ and StemCellRevivify™ combination therapy.
  • The study, published in the Journal of Translational Medicine, demonstrated significant improvements in healthspan, organ function, and regenerative capacity.
  • Collaborators included leading institutions such as the Buck Institute for Research on Aging and the University of Miami.
  • The combination therapy addresses both persistent senescence and regenerative decline, outperforming either approach alone.

Immorta Bio's study validates a dual-pronged approach to aging, combining senolytic clearance with regenerative therapies to achieve unprecedented lifespan extension. This strategy aligns with the broader industry shift toward targeting fundamental aging mechanisms rather than individual diseases. The collaboration with top research institutions underscores the scientific credibility of the findings, positioning Immorta Bio as a key player in the longevity biotechnology sector.

Clinical Translation
How quickly Immorta Bio can advance its therapeutic programs toward clinical development following these promising preclinical results.
Competitive Positioning
Whether the company can sustain its lead in the senolytic and regenerative therapy space amid growing competition.
Intellectual Property
The pace at which Immorta Bio expands its IP portfolio to protect its innovative combination therapy approach.